Hypertension as an underlying factor in heart failure with preserved ejection fraction

Journal of Clinical Hypertension

Volumn 12, Issue 4, 2010, Pages 277-283

  Volpe, Massimo ^a,b   McKelvie, Robert ^c   Drexler, Helmut ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PERINDOPRIL; PLACEBO; RENIN INHIBITOR; SPIRONOLACTONE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HEART ARREST; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DIASTOLE; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION; PROGNOSIS; STROKE VOLUME;

EID: 77952537910     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00253.x     Document Type: Review

References (40)

1. Redfield MM, Jacobsen SJ, Burnett JC. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
2. Cleland JG, Swedberg K, Follath F. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
3. Paulus WJ, Tschope C, Sanderson JE. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
4. Bursi F, Weston SA, Redfield MM. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
5. Owan TE, Hodge DO, Herges RM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
6. Bhatia RS, Tu JV, Lee DS. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
7. Masoudi FA, Havranek EP, Smith G. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003, 41:217-223.
8. Tribouilloy C, Rusinaru D, Mahjoub H. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008, 29:339-347.
9. Lenzen MJ, Scholte op Reimer WJ, Boersma E. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004, 25:1214-1220.
10. Zanchetti A, Cuspidi C, Comarella L. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. J Hypertens 2007, 25:2158-2167.
11. Cleland JG, Tendera M, Adamus J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
12. Yusuf S, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
13. McMurray JJ, Carson PE, Komajda M. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008, 10:149-156.
14. Levy D, Larson MG, Vasan RS. The progression from hypertension to congestive heart failure. JAMA 1996, 275:1557-1562.
15. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008, 26:1477-1486.
16. Peyster E, Norman J, Domanski M. Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. J Card Fail 2004, 10:49-54.
17. Fischer M, Baessler A, Hense HW. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003, 24:320-328.
18. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006, 111:81-98.
19. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004, 94:1533-1542.
20. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007, 27:15-26.
21. Muller-Brunotte R, Kahan T, Lopez B. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007, 25:1958-1966.
22. Martos R, Baugh J, Ledwidge M. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
23. van Heerebeek L, Borbely A, Niessen HW. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
24. Sciarretta S, Paneni F, Ciavarella GM. Evaluation of systolic properties in hypertensive patients with different degrees of diastolic dysfunction and normal ejection fraction. Am J Hypertens 2009, 22:437-443.
25. Nicoletti A, Heudes D, Mandet C. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996, 32:1096-1107.
26. Kuwahara F, Kai H, Tokuda K. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004, 43:739-745.
27. Sciarretta S, Ferrucci A, Ciavarella GM. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007, 20:784-791.
28. Lee KW, Blann AD, Lip GY. Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation. Am Heart J 2005, 150:756-766.
29. Williams ES, Shah SJ, Ali S. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: heart and Soul Study. Eur J Heart Fail 2008, 10:63-69.
30. Elesber AA, Redfield MM, Rihal CS. Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. Am Heart J 2007, 153:1081-1087.
31. Ma LN, Zhao SP, Gao M. Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease. Int J Cardiol 2000, 72:275-279.
32. Brutsaert DL, De Keulenaer GW. Diastolic heart failure: a myth. Curr Opin Cardiol 2006, 21:240-248.
33. Sciarretta S, Paneni F, Palano F. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009, 116:467-477.
34. Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs 2006, 6:373-381.
35. Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich) 2004, 6:441-445.
36. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008, 121:656-663.
37. Hogg K, McMurray J. The treatment of heart failure with preserved ejection fraction (" diastolic heart failure" ). Heart Fail Rev 2006, 11:141-146.
38. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006, 166:659-666.
39. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
40. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT). http://www.clinicaltrials.gov/show/NCT00094302, Accessed October 20, 2008